Literature DB >> 25281390

What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer?

Alberto Briganti1, Gianluca Giannarini2, R Jeffrey Karnes3, Giorgio Gandaglia4, Vincenzo Ficarra2, Francesco Montorsi4.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25281390     DOI： 10.1016/j.eururo.2014.09.025

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  4 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Authors:  Philipp Mandel; Clemens Rosenbaum; Raisa S Pompe; Thomas Steuber; Georg Salomon; Felix K Chun; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  World J Urol       Date:  2017-08-21       Impact factor: 4.226

Review 3.  Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy.

Authors:  Roger Li; Firas G Petros; Janet B Kukreja; Stephen B Williams; John W Davis
Journal:  Investig Clin Urol       Date:  2016-12-08

Review 4.  Effectiveness of extended pelvic lymphadenectomy in the survival of prostate cancer: a systematic review and meta-analysis.

Authors:  Herney Andrés García-Perdomo; Jose Jaime Correa-Ochoa; Ricardo Contreras-García; Siamak Daneshmand
Journal:  Cent European J Urol       Date:  2018-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.